These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 18164496)

  • 1. Porcine glucagon-like peptide-2: structure, signaling, metabolism and effects.
    Pedersen NB; Hjollund KR; Johnsen AH; Orskov C; Rosenkilde MM; Hartmann B; Holst JJ
    Regul Pept; 2008 Feb; 146(1-3):310-20. PubMed ID: 18164496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of glucagon-like peptide-2 in pigs: role of dipeptidyl peptidase IV.
    Hansen L; Hare KJ; Hartmann B; Deacon CF; Ugleholdt RK; Plamboeck A; Holst JJ
    Regul Pept; 2007 Feb; 138(2-3):126-32. PubMed ID: 17107718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purified PEGylated porcine glucagon-like peptide-2 reduces the severity of colonic injury in a murine model of experimental colitis.
    Qi KK; Wu J; Wan J; Men XM; Xu ZW
    Peptides; 2014 Feb; 52():11-8. PubMed ID: 24274971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regional metabolism of glucagon in anesthetized pigs.
    Deacon CF; Kelstrup M; Trebbien R; Klarskov L; Olesen M; Holst JJ
    Am J Physiol Endocrinol Metab; 2003 Sep; 285(3):E552-60. PubMed ID: 12759222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylated porcine glucagon-like peptide-2 improved the intestinal digestive function and prevented inflammation of weaning piglets challenged with LPS.
    Qi KK; Wu J; Deng B; Li YM; Xu ZW
    Animal; 2015 Sep; 9(9):1481-9. PubMed ID: 25963800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.
    Hansen L; Deacon CF; Orskov C; Holst JJ
    Endocrinology; 1999 Nov; 140(11):5356-63. PubMed ID: 10537167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.
    Wiśniewski K; Sueiras-Diaz J; Jiang G; Galyean R; Lu M; Thompson D; Wang YC; Croston G; Posch A; Hargrove DM; Wiśniewska H; Laporte R; Dwyer JJ; Qi S; Srinivasan K; Hartwig J; Ferdyan N; Mares M; Kraus J; Alagarsamy S; Rivière PJ; Schteingart CD
    J Med Chem; 2016 Apr; 59(7):3129-39. PubMed ID: 26986178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression, purification, and C-terminal amidation of recombinant human glucagon-like peptide-1.
    Zhang ZZ; Yang SS; Dou H; Mao JF; Li KS
    Protein Expr Purif; 2004 Aug; 36(2):292-9. PubMed ID: 15249052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effects of different doses of polyethylene glycosylated porcine glucagon-like peptide-2 on ulcerative colitis in male rats.
    Qi KK; Lv JJ; Wu J; Xu ZW
    BMC Gastroenterol; 2017 Mar; 17(1):34. PubMed ID: 28259136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.
    Plamboeck A; Holst JJ; Carr RD; Deacon CF
    Diabetologia; 2005 Sep; 48(9):1882-90. PubMed ID: 16025254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency.
    Sebokova E; Christ AD; Wang H; Sewing S; Dong JZ; Taylor J; Cawthorne MA; Culler MD
    Endocrinology; 2010 Jun; 151(6):2474-82. PubMed ID: 20382695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of PEGylated porcine glucagon-like peptide-2 therapy in weaning piglets challenged with lipopolysaccharide.
    Qi KK; Wu J; Xu ZW
    Peptides; 2014 Aug; 58():7-13. PubMed ID: 24874708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators.
    Dubé PE; Brubaker PL
    Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E460-5. PubMed ID: 17652153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J mice.
    Lee DW; Leinung MC; Grasso P
    Regul Pept; 2008 Oct; 150(1-3):62-5. PubMed ID: 18455249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catch-up growth in intrauterine growth-restricted piglets associated with the restore of pancreatic and intestinal functions via porcine glucagon-like peptide-2 microspheres.
    Qi KK; Wu J; Wen Jun Z; Bo D; Xu ZW
    Arch Anim Nutr; 2020 Dec; 74(6):462-475. PubMed ID: 33076701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system.
    Gadgaard S; Windeløv JA; Schiellerup SP; Holst JJ; Hartmann B; Rosenkilde MM
    Biomed Pharmacother; 2023 Apr; 160():114383. PubMed ID: 36780786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36.
    Hsieh J; Longuet C; Maida A; Bahrami J; Xu E; Baker CL; Brubaker PL; Drucker DJ; Adeli K
    Gastroenterology; 2009 Sep; 137(3):997-1005, 1005.e1-4. PubMed ID: 19482026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of variations in dose and method of administration on glucagon like peptide-2 activity in the rat.
    Kaji T; Tanaka H; Holst JJ; Redstone H; Wallace L; de Heuval E; Sigalet DL
    Eur J Pharmacol; 2008 Oct; 596(1-3):138-45. PubMed ID: 18762180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs.
    Trebbien R; Klarskov L; Olesen M; Holst JJ; Carr RD; Deacon CF
    Am J Physiol Endocrinol Metab; 2004 Sep; 287(3):E431-8. PubMed ID: 15126240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.